Patent 10517894 was granted and assigned to Iovance Biotherapeutics, Inc. on December, 2019 by the United States Patent and Trademark Office.
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.